| Identification | Back Directory | [Name]
Romosozumab | [CAS]
909395-70-6 | [Synonyms]
AMG785
AMG-785
CDP7851
AMG 785
CDP-7851
CDP 7851
Romosozumab
Research Grade Romosozumab(DHJ48701) |
| Hazard Information | Back Directory | [Uses]
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis[1][2]. | [in vivo]
Romosozumab (30 mg/kg; s.c. twice a week for 10 weeks) converts trabecular rods into trabecular plates in cynomolgus monkeys[1].
Romosozumab (3 and 30 mg/kg; s.c. once a week for 6 or 12 months) improves bone mass,
architecture, and bone strength, and maintains bone quality at the same time in mature cynomolgus monkeys with 4 months post-ovariectomy[2]. | Animal Model: | Male cynomolgus monkeys[1] | | Dosage: | 30 mg/kg | | Administration: | Subcutaneous injection; 30 mg/kg twice a week for 10 weeks | | Result: | Increased bone formation and plate-like trabecular morphology, and improved mechanical performance.
|
| [References]
[1] Paik J, Scott LJ. Romosozumab: A Review in Postmenopausal Osteoporosis. Drugs Aging. 2020 Nov;37(11):845-855. DOI:10.1007/s40266-020-00793-8
[2] Ominsky MS, et al. Romosozumab Improves Bone Mass and Strength While Maintaining Bone Quality in Ovariectomized Cynomolgus Monkeys. J Bone Miner Res. 2017 Apr;32(4):788-801. DOI:10.1002/jbmr.3036 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|